CaloCurb Clinical (Physician Regulated)

Calocurb^® CLINICAL is a practitioner-exclusive supplement that supports appetite control by working with the body’s natural hormonal signals. It features Amarasate^®, a clinically studied extract of New Zealand bitter hops, delivered in a delayed-release capsule designed to reach the small intestine, where it activates bitter taste receptors. This triggers the release of key satiety hormones, including GLP-1, CCK and PYY, which work together to significantly reduce hunger, cravings, and caloric intake. Fast-acting and plant-based, Calocurb^® CLINICAL offers a targeted, science-driven approach to supporting healthy weight management.

 In 2019, the first clinical study on Amarasate^® was conducted in a randomized, double-blind trial investigating its appetite suppressive effects during a 24-hour, water-only fast. Participants given Amarasate^® or placebo at hours 16 and 20 were evaluated for hunger and satiety with a standard visual analog scale (VAS) every 30 minutes after capsule administration. Amarasate^® participants reported an 80% reduction in hunger elevation scores compared to the placebo group. In a comparable water-fast study conducted in women, Amarasate^® supplementation led to a 100% suppression of hunger elevation and a 120% reduction in food cravings relative to placebo.

A more expansive study of adult men sought to correlate the subjective reduction in hunger from the first study with anorexigenic biomarkers, specifically GLP-1, CCK and PYY. The study also sought to investigate which was more efficacious, intragastric or intraduodenal delivery of Amarasate^®. In the randomized, double-blind study, the subjects were given either a placebo, intraduodenal Amarasate^® (delayed-release capsule), or intragastric Amarasate^® (immediate-release capsule) one hour before an ad libitum meal and subsequent snack. Both Amarasate^® delivery methods had significant elevations in GLP-1, CCK and PYY; however, the intragastric capsule also had significantly more adverse events than the intraduodenal capsule, likely due to the high amount of TAS2R bitter receptors in the stomach. Intraduodenal delivery of Amarasate^® resulted in 600% elevation from baseline of GLP-1 and CCK, and 50% elevation of PYY.

CLINICAL CONSIDERATIONS

Amarasate^® is a potent and effective appetite modulator, offering a targeted approach to supporting satiety and caloric control. It can be used independently or integrated into a comprehensive strategy for weight loss or maintenance. Calocurb^® CLINICAL may be co-administered with weight-loss medications to help manage breakthrough hunger or used during medication tapering to support appetite control. Alternatively, Calocurb^® CLINICAL can also be used as needed to support adherence to time-restricted eating or to help manage appetite and craving increases that may occur premenstrually.

Clinical Applications

• Reduces Appetite and Food Cravings
• Supports Long-Term Weight Management
• Stimulates Natural GLP-1, CCK and PYY Release
• Complements Lifestyle and Pharmaceutical Weight Loss Strategies
• Enhances Adherence to Intermittent Fasting and Time-Restricted Eating